Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Gets FDA OK for C. Difficile Test

NEW YORK (GenomeWeb News) – Nanosphere today said that the US Food and Drug Administration has granted 510(k) clearance for the firm's Clostridium difficile molecular test.

The test, which runs on Nanosphere's Verigene system, detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain, which is associated with increased severity of disease. The test automates the steps of bacterial DNA extraction, amplification, hybridization, and target detection on the Verigene system.

Nanosphere CEO Bill Moffitt noted in a statement that the firm has had four new products cleared by the FDA in the last 12 months. The other tests are for gram positive bloodstream infections, respiratory viruses, hypercoagulation, and warfarin metabolism.

Nearly 500,000 Americans are infected with C. difficile annually and is linked to more than 30,000 deaths per year in the US, said Nanosphere.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.